Chemical Compound

Bimatoprost

CAS Registry Number 155206-00-1
Bimatoprost chemical structure
Primary Record

Bimatoprost

Note: Only for scientific research or as raw materials for production.

In stock
7,218 g
Purity
99.8 %
CAS
155206-00-1

Compound Identifiers & Properties

CAS
155206-00-1
PubChem CID
5311027
SMILES
CCNC(=O)CCC/C=C\C[C@H]1[C@H](C[C@H]([C@@H]1/C=C/[C@H](CCC2=CC=CC=C2)O)O)O
Canonical SMILES
CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O

Names & Synonyms

  • Bimatoprost
  • Lumigan
  • Latisse
  • Prostamide
  • bimatoprostum
  • 155206-00-1
  • Lumigan (TN)
  • DURYSTA
  • Bimatoprost/Lumigan
  • AGN 192024
  • Bimatoprost in bulk
  • Lumiga n
  • Latisse (TN)
  • AC1NSJUW
  • ZOLYMBUS
  • AGN-192024
  • UNII-QXS94885MZ
  • RefChem:54542
  • BIMATOPROST [MI]
  • BIMATOPROST [INN]
  • BIMATOPROST [JAN]
  • QXS94885MZ
  • (5Z)-BIMATOPROST
  • BIMATOPROST [USAN]
  • D0Q2XF
  • BIMATOPROST [VANDF]
  • BIMATOPROST [MART.]
  • SCHEMBL24425
  • BIMATOPROST [WHO-DD]
  • C25H37NO4
  • CHEBI:51230
  • MLS006010039
  • US9271961, Bimatoprost
  • DTXSID30895042
  • AQOKCDNYWBIDND-FTOWTWDKSA-N
  • Bimataprost [USAN:INN:BAN]
  • Bimatoprost (JAN/USAN/INN)
  • BIMATOPROST [EMA EPAR]
  • Bimatoprost [USAN:INN:BAN]
  • MFCD03411999
  • GTPL1958
  • orb1305342
  • orb3025852
  • Bimatoprost (topical, alopecia)
  • Bimatoprost [USAN:INN:BAN:JAN]
  • CHEMBL1200963
  • GANFORT COMPONENT BIMATOPROST
  • BIMATOPROST [ORANGE BOOK]
  • S01EE03
  • AGN192024
  • BDBM220120
  • DTXCID401324598
  • GLXC-05106
  • EX-A1769
  • HY-B0191
  • ZINC4474405
  • 192024, AGN
  • ABP000616
  • C25-H37-N-O4
  • EBC-27016
  • MSK159263
  • AKOS015995566
  • ACN-037134
  • AM84507
  • AN-5283
  • CID5311027
  • CS-2085
  • CS-O-11612
  • DB00905
  • FB18599
  • FD10460
  • LS-181817
  • RP17728
  • CID:5311027
  • NCGC00181745-01
  • NCGC00181745-03
  • AS-35082
  • M052
  • SMR000058996
  • SID:283537485
  • AB0015029
  • B6165
  • FT-0650396
  • NS00007742
  • J1.596.089B
  • D02724
  • SBI-0654129.0001
  • (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide
  • (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
  • 206B001
  • A809623
  • C420823
  • EN300-21680860
  • SR-01000942224
  • (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
  • 17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide
  • I06-1275
  • I06-1277
  • Q2393348
  • SR-01000942224-1
  • 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-
  • 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-, (5Z)-
  • D000069580
  • (E)-7-[3,5-dihydroxy-2-[(E)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
  • 17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE
  • B0084-340237
  • (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide
  • (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide
  • 17-Phenyl-tri-norprostaglandin F2alpha-ethyl amide, >=95%, solid
  • (5E)-5-[4-(difluoromethoxy)benzylidene]-2-mercapto-1,3-thiazol-4(5H)-one
  • (5z)-7-{(1r,2r,3r,5s)-3,5-Dihydroxy-2-[(1e,3s)-3-Hydroxy-5-Phenylpent-1-Enyl]cyclopentyl}-N-Ethylhept-5-Enamide
  • (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenyl-pent-1-enyl]cyclopentyl]-N-ethyl-hept-5-enamide
  • 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (5Z)-
  • 5-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-1(alpha(Z),2beta(1E,3S*)3alpha,5alpha))-
  • (5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl)cyclopentyl)-N-ethylhept-5-enamide
  • (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide
  • (5Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]cyclopentyl]-N-ethyl-5-heptenamide; 5-Heptenamide, 7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-, (5Z)- (9CI); AGN 192024; Bimatoprost; Latisse; Lumigan; Prostamide; 5-Heptenamide, 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl]-N-ethyl-, [1R-[1alpha(Z),2beta(1E,3S*),3alpha,5alpha]]-; 17-Phenyltrinor-PGF2alpha ethylamide
  • (5Z)-N-Ethyl-7-[(1R)-2beta-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]-3alpha,5alpha-dihydroxycyclopentane-1alpha-yl]-5-heptenamide
  • (5Z)-N-Ethyl-7-[(1R,2R,3R,5S)-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]-3,5-dihydroxycyclopentane-1-yl]-5-hepteneamide
  • (5Z)-N-Ethyl-7-[2beta-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]-3alpha,5alpha-dihydroxycyclopentane-1alpha-yl]-5-hepteneamide
  • (5Z,9-alpha,11-alpha,13E,15S)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprosta-5,13-dienoic acid ethylamide
  • (E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
  • (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((E,3S)-3-hydroxy-5-phenylpent-1-enyl)cyclopentyl)-N-ethylhept-5-enamide
  • (Z)-7-[(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenyl-1-pentenyl]cyclopentyl]-N-ethyl-5-heptenamide
  • 15M
  • 5-Heptenamide, 7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-,(5Z)-
  • 5-Heptenamide, 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl]-N-ethyl-, [1R-[1alpha(Z),2beta(1E,3S*),3alpha,5alpha]]-
  • 5-Heptenamide,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ehtyl-,(5Z)